Spotlight on Olaratumab in the Treatment of Soft-tissue Sarcoma: Design, Development, and Place in Therapy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2017 Dec 22

PMID 29263653

Citations 1

Authors

Elizabeth J Davis

Rashmi Chugh

Affiliations

Soon will be listed here.

Abstract

Soft-tissue sarcoma (STS) is a heterogeneous group of tumors that arise from mesenchymal tissue. The prognosis of metastatic STS is poor with a life expectancy of 12-18 months. The mainstay of treatment is chemotherapy with an anthracycline. The addition of other chemotherapeutic agents to an anthracycline has been studied with limited success in improving outcomes for STS patients. Olaratumab is a fully human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor α (PDGFR-α) preventing binding of its ligands and receptor activation. This drug recently received the US Food and Drug Administration's accelerated approval for the treatment of advanced STS when combined with doxorubicin. This approval was based upon an improvement in overall survival of patients receiving the combination of doxorubicin and olaratumab compared to those receiving doxo-rubicin alone. In this review, we have analyzed the available literature on the development of olaratumab, its clinical utility, and its place in therapy. Based on early-phase clinical trials, olaratumab appears to be a promising agent for the treatment of STS.

Citing Articles

Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.

Song E, Ashcraft K, Lowery C, Mowery Y, Luo L, Ma Y EBioMedicine. 2019; 40:224-230.

PMID: 30711517 PMC: 6413473. DOI: 10.1016/j.ebiom.2019.01.046.

References

Schoffski P, Chawla S, Maki R, Italiano A, Gelderblom H, Choy E . Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028):1629-37. DOI: 10.1016/S0140-6736(15)01283-0. View

Italiano A, Mathoulin-Pelissier S, Cesne A, Terrier P, Bonvalot S, Collin F . Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2010; 117(5):1049-54. DOI: 10.1002/cncr.25538. View

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B . Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005; 4(3):369-79. DOI: 10.1158/1535-7163.MCT-04-0114. View

Heinrich M, Maki R, Corless C, Antonescu C, Harlow A, Griffith D . Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26(33):5352-9. PMC: 2651076. DOI: 10.1200/JCO.2007.15.7461. View

Verma S, Younus J, Stys-Norman D, Haynes A, Blackstein M . Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008; 34(4):339-47. DOI: 10.1016/j.ctrv.2008.01.005. View

Chawla S, Papai Z, Mukhametshina G, Sankhala K, Vasylyev L, Fedenko A . First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015; 1(9):1272-80. DOI: 10.1001/jamaoncol.2015.3101. View

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G . Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002; 8(10):3034-8. View

Chugh R, Griffith K, Davis E, Thomas D, Zavala J, Metko G . Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015; 26(7):1459-64. PMC: 4478972. DOI: 10.1093/annonc/mdv171. View

Movva S, Wen W, Chen W, Millis S, Gatalica Z, Reddy S . Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015; 6(14):12234-47. PMC: 4494935. DOI: 10.18632/oncotarget.3498. View

10.

DAdamo D, Anderson S, Albritton K, Yamada J, Riedel E, Scheu K . Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005; 23(28):7135-42. DOI: 10.1200/JCO.2005.16.139. View

11.

Shah G, Loizos N, Youssoufian H, Schwartz J, Rowinsky E . Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer. 2010; 116(4 Suppl):1018-26. DOI: 10.1002/cncr.24788. View

12.

Cassier P, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter M . Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012; 18(16):4458-64. DOI: 10.1158/1078-0432.CCR-11-3025. View

13.

Schoenfeld D, Rosenbaum C, Horton J, Wolter J, FALKSON G, DeConti R . A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982; 50(12):2757-62. DOI: 10.1002/1097-0142(19821215)50:12<2757::aid-cncr2820501211>3.0.co;2-j. View

14.

Heinrich M, Corless C, Duensing A, McGreevey L, Chen C, Joseph N . PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607):708-10. DOI: 10.1126/science.1079666. View

15.

Forsberg K, Valyi-Nagy I, Heldin C, Herlyn M, Westermark B . Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A. 1993; 90(2):393-7. PMC: 45668. DOI: 10.1073/pnas.90.2.393. View

16.

Carvalho I, Milanezi F, Martins A, Reis R, Schmitt F . Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005; 7(5):R788-95. PMC: 1242156. DOI: 10.1186/bcr1304. View

17.

Antman K, Crowley J, Balcerzak S, Rivkin S, Weiss G, Elias A . An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11(7):1276-85. DOI: 10.1200/JCO.1993.11.7.1276. View

18.

Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T . Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci. 2010; 15(5):654-60. DOI: 10.1007/s00776-010-1506-9. View

19.

Chiorean E, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N . A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014; 73(3):595-604. DOI: 10.1007/s00280-014-2389-9. View

20.

Tap W, Jones R, Van Tine B, Chmielowski B, Elias A, Adkins D . Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043):488-97. PMC: 5647653. DOI: 10.1016/S0140-6736(16)30587-6. View